Real-World Dalbavancin Use for Serious Gram-Positive Infections: Comparing Outcomes Between People Who Use and Do Not Use Drugs.

Sarah ZambranoMolly L ParasJoji SuzukiJeffrey C PearsonBrandon DionneHarry SchragerJason MalladaVeronica SzpakKatie Fairbank-HaynesMarlene KalterSara ProstkoDaniel A Solomon

Published in: Open forum infectious diseases (2024)

Dalbavancin was an effective treatment option for invasive gram-positive infections in our patient population. Despite higher rates of patient-directed discharge and loss to follow-up, PWUD had similar rates of clinical cure at 90 days compared to non-PWUD.

Keyphrases

gram negative
case report
multidrug resistant
type diabetes
drug induced
glycemic control
replacement therapy